Pre-eclampsia remains a significant challenge in maternal and fetal health worldwide, especially in developing countries like Indonesia. Marked by high blood pressure and organ damage during pregnancy, this condition often causes severe complications for both mother and baby if not detected early.
The recent publication in Circulation titled “Placental Growth Factor Screening in Early Pregnancy for the Prevention of Pre-eclampsia in Asian Populations” is a groundbreaking achievement in pre-eclampsia research. As part of a multicenter study across Asia, Indonesia played a crucial role in this largest-ever investigation of its kind, contributing valuable data to efforts in pre-eclampsia prevention. Read more about the article through this link.
The study focuses on using Placental Growth Factor (PLGF) as a biomarker for early detection. By combining PLGF blood tests with Doppler ultrasound of uterine arteries and maternal clinical history, it establishes an effective screening approach to identify high-risk pregnancies early, enabling timely interventions.
For Indonesia, this research underscores the critical need to integrate systematic pre-eclampsia screening into routine prenatal care, especially in the first trimester. Affordable and accessible tools like PLGF tests, paired with ultrasound, offer practical solutions to reduce pre-eclampsia burdens, even in low-resource settings.
This milestone not only elevates Indonesia’s role in global maternal health research but also sets the stage for further innovations in maternal and fetal care. As the findings move into clinical practice, the commitment of healthcare providers and policymakers is key to ensuring safer pregnancies and healthier outcomes for mothers and babies.
This study reflects the power of collaboration and innovation in addressing urgent health challenges, marking a new chapter in pre-eclampsia care.
Full Article: https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.124.069907
For more studies, visit prenatal.or.id/research
